Ascendis Pharma
A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.
The firm uses its innovative TransCon technologies to address unmet medical needs.
In September 2020, Ascendis announced positive preliminary six-month results from the open-label extension portion of PaTH Forward, a global Phase II trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism.
EvaluatePharma’s sell-side consensus sees Transcon PTH generating $847 million of 2026 sales.
Latest Ascendis Pharma News & Features
30 November 2023
15 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze